Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). Aastrom is a development-stage company focused on research and product development for ex vivo human cell production and gene therapy. The company operates in one reportable segment and has received CE Mark approval for its AastromReplicell System and specific cell therapy kits, enabling sales in Europe. As of March 31, 2002, the company had accumulated losses of approximately $91.8 million since inception.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2002 | Nine Months Ended Mar 31, 2002 | Balance Sheet (Mar 31, 2002) |
|---|---|---|---|
| Total Revenues | $232,000 | $650,000 | N/A |
| Net Loss | $(2,072,000) | $(5,985,000) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.14) | N/A |
| Research & Development Expenses | $1,439,000 | $4,042,000 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $10,953,000 |
| Short-term Investments | N/A | N/A | $1,000,000 |
| Total Current Assets | N/A | N/A | $13,442,000 |
| Total Current Liabilities | N/A | N/A | $917,000 |
| Working Capital | N/A | N/A | $12,525,000 |
Revenue Composition: Revenues are primarily derived from grants ($232,000 for the quarter; $570,000 for the nine months) and minimal product sales/rentals ($0 for the quarter; $80,000 for the nine months).
Material Changes vs. Prior Period
- Revenue: Quarterly revenue increased to $232,000 from $191,000 in the prior year quarter, driven by grant funding. Nine-month revenue remained relatively flat at $650,000 compared to $653,000 in the prior year.
- Expenses: Total costs and expenses increased to $2,365,000 for the quarter (from $2,054,000) and $6,924,000 for the nine months (from $5,225,000). This increase is attributed to expanded research and development activities and higher selling, general, and administrative (SG&A) expenses.
- Net Loss: The net loss widened to $2,072,000 for the quarter (from $1,715,000) and $5,985,000 for the nine months (from $4,037,000). The increase in loss per share for the nine-month period (from $0.12 to $0.14) was exacerbated by an increase in the weighted average number of shares outstanding due to equity financing.
- Liquidity: Cash and cash equivalents increased by $294,000 to $10,953,000, supported by $7,849,000 in equity financing during the nine-month period.
Guidance, Outlook, and Risks
Outlook and Guidance: Management does not expect to generate positive cash flows from operations for at least the next several years. Based on current funding, the company expects available cash to be sufficient to finance planned activities through the end of calendar year 2002. Future operations depend heavily on obtaining additional funding through public/private equity sales, grants, or strategic collaborations.
Management Commentary: The company has initiated external site testing of its AastromReplicell System and DC-I cell product. While European commercialization has begun, U.S. commercialization requires FDA approval. The company is pursuing additional sources of financing to support clinical trials and commercialization.
Material Risks and Contingencies:
- Delisting Risk: The company's stock price fell below the $1.00 minimum bid price required for Nasdaq listing. The company was notified it would be delisted if compliance is not regained by May 28, 2002.
- Supply Chain: Plexus Services Corp., the manufacturer of the AastromReplicell System instrument units, has elected to terminate its Manufacturing Supply Agreement effective February 2004. The company must secure a new agreement or alternate supplier.
- Regulatory Approval: Commercialization in the U.S. is contingent upon FDA approval, which requires successful clinical trials demonstrating safety and efficacy. Delays or failures in trials could severely limit operations.
- Capital Needs: The company has never been profitable and has accumulated significant losses. Failure to raise additional capital could force substantial reductions in operations or curtailment of planned activities.
Investor Verification Checklist
- Nasdaq Compliance: Verify if the company has regained compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Manufacturing Agreement: Confirm the status of negotiations for a new manufacturing supply agreement to replace the contract with Plexus Services Corp. expiring in February 2004.
- Cash Runway: Assess the sufficiency of the $11.95 million in liquid assets to fund operations through the end of 2002 and beyond, given the burn rate of approximately $6.4 million for the nine-month period.
- Equity Dilution: Review the impact of outstanding warrants (2.6 million shares) and options (3.9 million shares) on future shareholder dilution.
- Clinical Trial Progress: Monitor the status of Phase III trials for SC-I and CB-I kits and Phase I/II trials for OC-I, as these are critical for future revenue generation.